A heat killed Porphyromonas gingivalis bacterium expressing a homogenous lipid A structure having a molecular negative mass ion of 1368, 1435/1449, or 1690/1768 is used as an immunomodulator. The immunomodulator may be used in combination with an antigen of interest to potentiate or restrain a host immune response toward the selected antigen.

The present invention relates to polypeptide HP, or a polynucleotide sequence encoding polypeptide HP, or a host cell comprising said polynucleotide sequence, or a host cell comprising an expression vector comprising said polynucleotide sequence, for use in the treatment and/or prevention of a disorder in a subject; wherein said disorder is an inflammatory disorder and/or an autoimmune disorder; wherein said polypeptide has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof; and wherein said polynucleotide sequence encodes a polypeptide which has at least 75% identity to SEQ ID NO 2, SEQ ID NO 4 or SEQ ID NO 6 or variants, homologues, fragments or derivatives thereof and/or wherein said polynucleotide sequence has at least 75% identity to SEQ ID NO 1, SEQ ID NO 3 or SEQ ID NO 5 or variants, homologues, fragments or derivatives thereof.

This invention relates to the delivery of heterologous peptides or proteins such as therapeutic peptides, therapeutic proteins or antigens to mucosal sites using vesicles derived from the outer membrane of commensal bacteria, recombinant bacteria capable of producing such vesicles, and methods for the production of such vesicles. The invention further relates to an inducible expression system for use in recombinant bacteria.

Provided herein are methods and compositions related to treating or preventing seizures. In some aspects, provided herein are methods of treating or preventing seizures in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

Described are compositions and methods for treating inflammatory bowel diseases in a subject in need thereof. In certain aspects, the disclosure provides methods of treating a subject diagnosed with Irritable Bowel Disease (IBD), the method comprising administering to the subject an agent to reduce the number or pathogenic effects of a B. fragilis strain, wherein the subject is diagnosed with IBD by detecting the presence of the B. fragilis strain or a B. fragilis toxin in a biological sample of the patient.

This disclosure provides therapeutic compositions and methods for inducing an anti-inflammatory response and/or treating inflammation in the gastrointestinal tract and/or accumulating gut microbial antigen-specific anti-inflammatory T cells in a patient in need thereof.

Bacterial cold-water disease (BCWD) vaccines for fish comprising, consisting of, or consisting essentially of, a live, attenuated Flavobacterium psychrophilum strain derived from a US149 strain and/or a US063 (ST278) strain, particularly formulated for fish of the Salmo and Salvelinus genera are disclosed. Disclosed embodiments also concern isolated, livem nonattenuated or attenuated Flavobacterium psychrophilum strains derived from an unattenuated strain having a cumulative percent mortality (CPM) in fish species in the Salmo and Salvelinus genera challenged with the strain of 40% or greater prior to attenuation. Treating BCWD comprises administering an effective amount of a disclosed vaccine to fish species primarily of the Salmo and Salvelinus genera. Making a BCWD vaccine comprises first identifying a highly virulent Flavobacterium psychrophilum bacterial strain for a target genus or species of interest, attenuating the highly virulent Flavobacterium psychrophilum bacterial strain, and then using the attenuated strain to produce a vaccine.

This disclosure provides therapeutic compositions and methods for inducing an anti-inflammatory response and/or treating inflammation in the gastrointestinal tract and/or accumulating gut microbial antigen-specific anti-inflammatory T cells in a patient in need thereof.

Provided herein are methods and compositions related to Prevotella EVs useful as therapeutic agents.

The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.